Table 1. Baseline characteristics of participants*.
| HIV-infected | Controls | p-value | |
|---|---|---|---|
| N = 12 | N = 45 | ||
| Age–years | 33 (30–47) | 43 (31–62) | 0.12 |
| Male gender—N (%) | 12 (100) | 22 (49) | 0.001 |
| Previous YFV–N (%) | 4 (33) | 16 (36) | 0.56 |
| Single lifetime YFV dose | 4 (33) | 10 (22) | |
| Two lifetime YFV doses | 0 | 6 (13) | |
| YF NAb, Log10mIU/mL | |||
| All participants | 0 (0–3.0) | 2.4 (0–3.3) | 0.48 |
| Participants with prior YFV | 3.3 (2.9–4.0) | 3.4 (3.2–4.0) | 0.71 |
| CD4 T count–cells/mm3 | 722 (526–795) | 941 (807–1470) | 0.003 |
| CD4/CD8 ratio | 0.7 (0.5–0.8) | 1.6 (1.3–2.6) | <0.0001 |
| KT ratio–nM/μM | 35.9 (33.4–43.9) | 31.3 (27.5–37.7) | 0.06 |
| Viremia by Human Pegivirus–N (%) | 8 (66.7) | 12 (26.7) | 0.016 |
| Undetectable# HIV VL–N (%) | 8 (67) | - | - |
HIV, human immunodeficiency virus; YFV, Yellow Fever Vaccine; YF NAb, Yellow Fever-specific neutralizing antibodies; KT, kynurenine/tryptophan; VL, viral load.
*Continuous variables are presented as medians and interquartile ranges.
#Considered undetectable if below 40 copies/ml.